NDAORALTABLETPriority Review
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
PHOSLO (calcium acetate) by Fresenius Kabi is (calcium acetate capsules) when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration. First approved in 1990.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHOSLO (calcium acetate) is an oral phosphate binder indicated for chronic kidney disease and peritoneal dialysis patients. It works by combining with dietary phosphate during meals to form an insoluble complex that is excreted in feces, lowering serum phosphorus levels. This mechanism addresses hyperphosphatemia, a critical complication in renal disease management.
LOE Approaching
As an approaching LOE product with low competitive pressure (30%), PHOSLO teams are likely focused on lifecycle management and cost optimization rather than expansion.
Mechanism of Action
(calcium acetate capsules) when taken with meals, combines with dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentration.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis
Started Dec 2004
138 enrolled
Peritoneal DialysisChronic Kidney Disease
Career Relevance
Working on PHOSLO offers limited career growth opportunities due to zero current job postings, approaching loss of exclusivity, and minimal clinical development. However, it provides solid foundation experience in niche renal therapeutics and established product management within a stable, mature market.
Brand Manager
Worked on PHOSLO at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.